What is Maat?
Founded in 2014 and headquartered in Lyon, France, Maat Pharma is dedicated to pioneering microbiome restoration therapies. The company's core mission involves leveraging biotherapeutics to combat severe diseases, positioning itself at the forefront of innovative medical treatments. Its clinical-stage focus indicates a commitment to rigorous development and validation of its therapeutic approaches.
How much funding has Maat raised?
Maat has raised a total of $100.7M across 6 funding rounds:
Unspecified
$1.3M
Unspecified
$1.1M
Series A
$11.2M
Series B
$29.5M
Share Placement
$14M
Debt
$43.7M
Unspecified (2015): $1.3M with participation from Seventure Partners
Unspecified (2015): $1.1M led by Seventure Partners
Series A (2016): $11.2M supported by Seventure Partners
Series B (2020): $29.5M featuring Crédit Mutuel Innovation, Biocodex, Seventure Partners, Bpifrance, and SymBiosis
Share Placement (2025): $14M backed by Biocodex, RiPSIM Technologies, and Bpifrance Investissement
Debt (2025): $43.7M with participation from European Investment Bank
Key Investors in Maat
Seventure Partners
Seventure Partners is an active partner of innovative companies in the fields of digital technologies and life sciences. They invest in a broad range of sectors including health, nutrition, fintech, and sustainable blue economy initiatives. Their client base includes entrepreneurs seeking investment opportunities as well as innovative startups in various high-tech segments. Seventure also focuses on addressing environmental challenges through biotechnologies and digital solutions.
European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution.
Crédit Mutuel Innovation
Undisclosed investor participating in the funding round.
What's next for Maat?
The recent major strategic investment and the substantial overall capital raised suggest Maat Pharma is poised for significant scaling and advancement of its clinical pipeline. This influx of financing will likely accelerate research and development, facilitate broader clinical trials, and potentially support market entry strategies for its microbiome restoration therapies. The company's trajectory indicates a strong potential for growth and impact in the oncology and biotherapeutics sectors.
See full Maat company page
